Beta

Decoy therapeutics inc.DCOY.US Overview

US StockHealthcare
(No presentation for DCOY)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

DCOY AI Insights

DCOY Overall Performance

DCOY AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

DCOY Recent Performance

-0.64%

Decoy therapeutics inc.

-1.10%

Avg of Sector

-0.49%

S&P500

DCOY PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check DCOY's Trend

DCOY Key Information

DCOY Valuation Metrics

DCOY Profile

Price of DCOY

DCOY FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

DCOY Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-18.52
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
15.86
PB Ratio
0.49
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-18.52
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
15.86
PB Ratio
0.49
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is DCOY's latest earnings report released?

    The most recent financial report for Decoy therapeutics inc. (DCOY) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating DCOY's short-term business performance and financial health. For the latest updates on DCOY's earnings releases, visit this page regularly.

  • How much cash does DCOY have?

    At the end of the period, Decoy therapeutics inc. (DCOY) held Total Cash and Cash Equivalents of 10.71M, accounting for 0.97 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is DCOY's EPS continuing to grow?

    According to the past four quarterly reports, Decoy therapeutics inc. (DCOY)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 42.9. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of DCOY?

    Decoy therapeutics inc. (DCOY)'s Free Cash Flow (FCF) for the period is -1.14M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 53.06% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of DCOY?

    The latest valuation data shows Decoy therapeutics inc. (DCOY) has a Price-To-Earnings (PE) ratio of -0.28 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.